RNS Number : 6271W
Hutchmed (China) Limited
16 March 2026
Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Monday, March 16, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP") on March 13, 2024 to the following person discharging managerial responsibilities were vested on March 13, 2026:-
Award Holder
Number ofordinary shares
DrWeiguo Su(Executive Director, Chief Executive Officer and Chief Scientific Officer)
19,913
The notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.
Dr Weiguo Su
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Dr Weiguo Su
2
Reason for the notification
a)
Position/status
Executive Director, Chief Executive Officer and Chief Scientific Officer
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
HUTCHMED (China) Limited
b)
LEI
2138006X34YDQ6OBYE79
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument Identification code
Ordinary Shares of US$0.10 Ordinary Share with DI ISIN: KYG4672N1016
b)
Nature of the transaction
Vesting of awards granted onMarch13, 2024under HUTCHMED's LTIP
c)
Price(s) and volume(s)
Price(s)
Volume(s)
Nil
19,913ordinary shares
d)
Aggregated information
-
Aggregated volume
-
Price
N/A
e)
Date of the transaction
2026-03-13
f)
Place of the transaction
Outside a trading venue
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
CONTACTS
Freddie Barnfield / Jeffrey Wong / Duncan Monteith
+44 20 7260 1000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBBGDXCUBDGLX
